STAND. COM. REP. NO. †986-16


Honolulu, Hawaii

††††††††††††††† , 2016


RE:†† H.B. No. 1013

††††† H.D. 3




Honorable Joseph M. Souki

Speaker, House of Representatives

Twenty-Eighth State Legislature

Regular Session of 2016

State of Hawaii




†††† Your Committee on Judiciary, to which was referred H.B. No. 1013, H.D. 2, entitled:




begs leave to report as follows:


†††† The purpose of this measure is to authorize a manufacturer of an investigational drug, biological product, or device to make available, and an eligible patient to request, the manufacturer's investigational drug, biologic product, or device.


†††† This measure also:


†††† (1)† Prohibits the State from blocking access by an eligible patient to an investigational drug, biologic product, or device;


†††† (2)† Grants immunity to manufacturers and other persons involved in providing experimental drugs, products, or devices to consenting patients with terminal illnesses from suit for any harm that results; and


†††† (3)† Relieves the heirs of a patient who dies while being treated with an investigational drug, biologic product, or device of any liability for any outstanding debt for the treatment.


†††† The Goldwater Institute testified in support of this measure.† The Department of the Attorney General testified in opposition.† The Hawaii Medical Service Association provided comments.


†††† Your Committee finds that right to try laws give terminally ill patients, with the recommendation of their treating physician, the opportunity to access investigational new drugs that have passed Phase I of the Federal Food and Drug Administration approval process, if their doctor believes, at this stage of the disease, the drug is the patient's last and best chance.† Your Committee notes that clinical trials accept only about three percent of given patients afflicted with the condition for which the therapy is being tested.


†††† Right to try laws are designed for patients who are ineligible or unable to access current clinical trials for the needed investigational new drugs.† Your Committee believes this measure may be especially important for residents of Hawaii, who may have great difficulty in their current conditions traveling the long distances to clinical trial locations.


†††† Your Committee has amended this measure to:


†††† (1)† Clarify that the patientís estate will be liable for any outstanding debt related to the treatment unless an agreement states otherwise;


†††† (2)† Clarify that a licensing board may not sanction a health care provider's licensing or certification based in any way on the provider's recommendation to an eligible patient of an investigational drug, biological product, or device that is being developed to treat the type of terminal illness that afflicts the patient; and


†††† (3)† Make technical, nonsubstantive amendments for clarity, consistency, and style.


†††† As affirmed by the record of votes of the members of your Committee on Judiciary that is attached to this report, your Committee is in accord with the intent and purpose of H.B. No. 1013, H.D. 2, as amended herein, and recommends that it pass Third Reading in the form attached hereto as H.B. No. 1013, H.D. 3.


Respectfully submitted on behalf of the members of the Committee on Judiciary,